Safety Considerations in Anti-CD20 Therapy for MS

What are the key safety considerations for anti-CD20 therapy in multiple sclerosis?

The key safety considerations for anti-CD20 therapy in multiple sclerosis are infection risk—particularly in patients with higher disability, comorbidities, or prior immunosuppressive treatments—requiring systematic monitoring of immunoglobulin and lymphocyte levels with intensified surveillance after 12 months of continuous therapy when cumulative immunosuppression becomes most pronounced.

Abstract

Infections represent the primary safety concern with anti-CD20 therapy in multiple sclerosis, with serious infection rates ranging from 5.0% to hospitalization in 16 of 416 patients across studies. Bacterial infections, particularly urinary and respiratory tract infections, predominate, though varicella-zoster virus infections occurred in seven patients in one cohort. Infection risk increases substantially with longer treatment duration (OR 1.6), higher disability levels (EDSS OR 2.0), comorbidities (OR 3.3), and prior exposure to multiple MS therapies (aHR 1.7). Hypogammaglobulinemia develops in approximately one-third of patients, with lower IgG levels correlating with serious infections, while lower lymphocyte counts independently predict VZV infections. Infusion-related reactions affect up to 77% of patients but are predominantly mild-to-moderate with no grade 4 events reported. Late-onset neutropenia occurs after a median of 90 days, affecting 19 patients across studies and requiring G-CSF or antibiotics in 70% of cases. Safety monitoring should include baseline assessment of comorbidities, age, and EDSS scores, with ongoing surveillance of immunoglobulin levels every 4-6 months and lymphocyte counts, particularly after 12 months of continuous therapy when cumulative immunosuppression becomes most evident.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

Screening

We screened in sources based on their abstracts that met these criteria:

• Multiple Sclerosis Population: Does the study include patients diagnosed with multiple sclerosis (any subtype: relapsing-remitting, primary progressive, or secondary progressive)?
• Anti-CD20 Intervention: Does the study involve anti-CD20 monoclonal antibody therapy (including but not limited to rituximab, ocrelizumab, ofatumumab, or ublituximab)?
• Safety Outcomes Reported: Does the study report safety outcomes, adverse events, or safety-related endpoints?
• Appropriate Study Design: Is the study design one of the following: randomized controlled trial, cohort study, case-control study, case series with ≥10 patients, systematic review, or meta-analysis?
• Human Clinical Study: Is this a human clinical study (not an in vitro, animal, or preclinical research study)?
• Full-Text Publication: Is this a full-text article (not a conference abstract, letter to editor, editorial, or commentary)?
• MS-Specific Analysis: If the study includes patients with conditions other than multiple sclerosis, does it provide separate analysis or subgroup data specifically for MS patients?
• Original Data: Is this an original study or does it provide additional safety information not previously reported (i.e., not a duplicate publication or secondary analysis of the same dataset without new safety data)?

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.

Data extraction

We extracted each data column from each paper:

• Study Population: Extract key characteristics of the multiple sclerosis patient population that could affect anti-CD20 safety considerations, including patient age range, MS subtype, disease duration, prior MS treatments, baseline disability level, comorbidities, sample size, and follow-up duration.
• Anti-CD20 Treatment: Extract details about the anti-CD20 therapy regimen that could impact safety profile, including specific anti-CD20 drug used, dosing regimen, treatment duration, any dose modifications, and concomitant medications.
• Infection Events: Extract all infection-related safety events specifically in MS patients receiving anti-CD20 therapy, including types of infections, specific pathogens identified, infection severity, incidence rates, time to infection onset, and outcomes of infections.
• Non-Infection Adverse Events: Extract all non-infectious adverse events and safety concerns related to anti-CD20 therapy in MS patients, including infusion-related reactions, malignancies, cardiovascular events, and treatment discontinuations due to safety.
• Laboratory Changes: Extract laboratory monitoring data relevant to anti-CD20 safety in MS patients, including B-cell counts, total lymphocyte counts, immunoglobulin levels, and timing of laboratory changes.
• Risk Factors: Extract identified risk factors that increase safety risks, including patient demographic factors, disease-related factors, treatment-related factors, and statistical associations.
• Special Populations: Extract safety considerations specific to special MS populations receiving anti-CD20 therapy, including pediatric/adolescent MS patients, elderly patients, and those with significant comorbidities.
• Safety Monitoring: Extract recommended approaches for safety monitoring in MS patients on anti-CD20 therapy, including baseline screening recommendations, laboratory monitoring schedules, and infection prevention strategies.

Results

Characteristics of Included Studies

The review identified 10 sources examining anti-CD20 therapy safety in multiple sclerosis, comprising systematic reviews and cohort studies. Sample sizes ranged from 19 to 4181 patients, with follow-up durations spanning from approximately 10 months to 33 months.

Infection-Related Safety Events

Infections emerged as the primary safety concern across all studies. The Fernandes cohort of 160 MS patients reported a 10.6% incidence of post-administration infectious adverse events, with 5.0% categorized as serious infections. The Oksbjerg study reported 16 hospitalized patients due to infections during up to three years of follow-up. Overall annualized infection rate was 0.8 per patient-year, with infections occurring after a mean time of 263 days.

Non-Infectious Adverse Events

Infusion-related reactions represented the most common non-infectious adverse event, with mild to moderate reactions occurring in up to 77% of patients from some studies. Neutropenia emerged as a distinct complication noted in a case series. Treatment discontinuations due to adverse events or intolerance occurred in several patients across the studies.

Laboratory Changes and Immunological Effects

B-cell depletion patterns varied across studies, and hypogammaglobulinemia developed in approximately one-third of patients, with IgM often more affected than IgG.

Risk Factors for Adverse Events

Multiple risk factors for infection were identified: older age, higher EDSS scores, presence of comorbidities, and prior MS treatments.

Special Populations

Pediatric-onset MS patients demonstrated distinct safety profiles and treatment responses, with careful considerations necessary for the elderly and those with significant comorbidities.

Safety Monitoring Approaches

Monitoring recommendations included baseline screening of comorbidities and laboratory parameters relevant to infection risks, with recommendations for intensified monitoring of IgG levels and lymphocyte counts throughout treatment duration.

Synthesis

Anti-CD20 therapy demonstrates consistent efficacy for MS while maintaining an acceptable safety profile, though serious infections and immunological changes require systematic monitoring. The heterogeneity in infection rates across studies highlights the importance of stratifying risk based on treatment duration, baseline disability, and comorbidities.